Memantine Versus Donepezil in Early Stages of Alzheimer's Disease
DementiaAlzheimer TypeIt is well known that in the brain of the patients with Alzheimer's disease there is a glutamatergic hyperstimulation leading to neuronal death. Memantine is a low affinity antagonist of NMDA glutamate receptors. The use of this drug in the early phases of the disease could provide neuroprotective effects and delay of progression. The effects of memantine should be compared to those of donepezil, which is the most prescribed anticholinesterase drug.
Combining a Caregiver Intervention With Aricept Treatment for Mild to Moderate Alzheimer's Disease...
Alzheimer DiseaseCaregiversA unique multinational study was conducted simultaneously in the USA, England and Australia. The goals of the study were to answer two questions: Does psychosocial support for the family enhance the effectiveness of drug treatment for Alzheimer's disease? Is the added value of psychosocial support the same in all 3 countries?
Effect of Testosterone Therapy in Men With Alzheimer's Disease and Low Testosterone
Alzheimer's DiseaseHypogonadismTreatment with testosterone can improve performance on tests of spatial ability in men with low testosterone levels and Alzheimer's disease. Improved performance on these tests may mean an improved ability to get around in one's environment without getting lost or injured. This could have a positive impact on both patients and those who care for them. We will investigate what areas of the brain are involved in these improvements in spatial ability. This will be done using a PET scan, which creates a 3-dimensional image of the brain that can allow us to see how the brain functions.
Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI)...
Alzheimer's DiseaseThe purpose of this study is to characterize the progression of disease using volumetric MRI techniques and cognitive outcome measures in patients with moderate dementia of the Alzheimer's type treated with open-label memantine.
Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia
Frontal Lobe DementiaFrontotemporal Lobe Dementia1 moreThe primary objective of the study is to determine whether memantine is effective in slowing the rate of behavioral decline in frontotemporal dementia. The secondary objective of the study is to assess the safety and tolerability of long-term treatment with memantine in patients with frontotemporal dementia (FTD) or semantic dementia (SD). To determine whether memantine is effective in slowing the rate of cognitive decline in frontotemporal dementia. To evaluate whether memantine delays or decreases the emergence of parkinsonism in frontotemporal dementia. The tertiary objective of the study is to determine whether treatment with memantine affects changes in weight
A Study of the Safety and Efficacy of Memantine in Moderate to Severe Alzheimer's Disease
Dementia of the Alzheimer's TypeThe objective of this study is to evaluate the safety, tolerability, and efficacy of memantine compared to placebo in outpatients diagnosed with moderate-to-severe dementia of the Alzheimer's type on a concurrent acetylcholinesterase inhibitor (AChEI).
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's...
Alzheimer's DiseaseDementia1 moreThe goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
SGS742 in Patients With Mild to Moderate Alzheimer's Disease (AD)
Alzheimer's DiseaseThe purpose of this trial is to determine the effect of a new drug, SGS742, on memory and cognition in patients with mild to moderate Alzheimer's disease.
An Evaluation of the Safety and Efficacy of Memantine in Agitated Patients With Moderate to Severe...
Alzheimer's DiseaseAbout 65% of patients with severe Alzheimer's Disease (AD) will have symptoms of agitation. There are drawbacks associated with the currently available therapeutic interventions for agitation associated with Alzheimer's Disease. In a recent trial, in the group of patients with moderate to severe AD treated with memantine, there were fewer incidences of agitation. It is hypothesized that memantine will be effective in reducing the symptoms of agitation associated with moderate to severe Alzheimer's Disease.
The Safety and Efficacy of Neramexane in Patients With Moderate to Severe Alzheimer's Disease
Alzheimer's DiseaseMemory loss and difficulties with thinking associated with Alzheimer's disease may be due to chronic release of a brain chemical called glutamate. Glutamate helps transmit messages between nerve cells through interaction with a certain type of receptor (N-methyl-D-aspartate, NMDA) on the cell. Neramexane is a new drug that blocks the effects of excessive glutamate at the receptor (NMDA receptor antagonist).